Encapsulated islet transplants restore blood sugar control in diabetic mice
Researchers at Penn State have developed a biomimetic encapsulation method for islet cell transplants that allows diabetic mice to maintain normal blood sugar without immunosuppressants. The technique mimics the protective properties of the zona pellucida membrane found in mammalian eggs.
Why it matters
This breakthrough could significantly improve the success rate and safety of islet transplantation for Type 1 diabetes patients by eliminating the need for long-term immunosuppressive drugs.
Islet transplantation, in which insulin-producing islet cells from a donor are implanted into a patient’s liver, is a promising therapy for type 1 diabetes. To prevent rejection of the donated cells, however, recipients need to continuously take immunosuppression drugs. Using a new type of cell encapsulation, researchers at The Pennsylvania State University demonstrated that diabetic mice could maintain normal blood glucose levels for 100 days, without requiring immunosuppressants. This represents a substantially longer time period than traditional cell therapies for diabetes.
The article reports on scientific research findings in a factual, objective manner without political or social commentary.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in